Vaccinex, Inc.

VCNX · OTC · United States

Share price · VCNX

$1.25+0.15 (+13.64%) 3M

no price since 18 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VCNX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Aug 2026+60.3%

    Nothing announced by VCNX that day or the session before.

  2. 3 Aug 2026+35.3%

    Nothing announced by VCNX that day or the session before.

  3. 31 Jul 2026-28.0%
  4. 21 Jul 2026+35.6%

    Nothing announced by VCNX that day or the session before.

  5. 20 Jul 2026-24.3%

    Nothing announced by VCNX that day or the session before.

  6. 29 Jun 2026+29.9%
  7. 23 Jun 2026-24.5%

    Nothing announced by VCNX that day or the session before.

  8. 4 Jun 2026+29.9%

    Nothing announced by VCNX that day or the session before.

  9. 16 Mar 2026+42.9%

    Nothing announced by VCNX that day or the session before.

  10. 6 Mar 2026+31.1%

    Nothing announced by VCNX that day or the session before.

Share of unusual movement by asset

For each asset, the share of VCNX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Pepinemab
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—4%
Sessions with no dated event—95%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
SEMA4DMonoclonal antibody
Alzheimer's DiseaseHead and Neck Squamous Cell Carcinoma
Early Alzheimer's Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
PepinemabPhase 1/2Metastatic Pancreatic Adenocarcinoma
Est. primary completion 2028-12-31 · NCT05102721 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (10)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-Q3$0.1M$3.2M$2.9M$5.7M-$3.2M operating cash flowreport ↗

Vaccinex reported revenue of $0.05M, up 150.0% YoY, with R&D spend of $3.17M, down 27.3% YoY. Cash and equivalents stood at $2.91M, and the company posted a net loss of $5.73M, equivalent to a quarterly net burn of $5.73M.

The filing discloses substantial doubt about the company’s ability to continue as a going concern, citing cash used in operations of $12.3M for the nine months ended September 30, 2024 and an accumulated deficit of $355.2M. No financial guidance or clinical pipeline updates were reported.

View 9 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-Q2$0.2M$3.9M$0.2M$5.6M-$4.4M operating cash flowreport ↗
2024-Q1$0.1M$3.4M$3.0M$3.9M-$4.6M operating cash flowreport ↗
2023-Q3<$0.1M$4.4M$0.1M$4.9M-$3.1M operating cash flowreport ↗
2023-Q2—$5.0M$1.9M$7.1M-$5.5M operating cash flowreport ↗
2023-Q1$0.6M$3.8M$3.3M$5.0M-$5.0M operating cash flowreport ↗
2022-Q3$0.1M$3.4M$7.2M$4.8M-$4.2M operating cash flowreport ↗
2022-Q2—$3.8M$11M$5.4M-$5.3M operating cash flowreport ↗
2022-Q1—$3.0M$17M$4.6M-$5.0M operating cash flowreport ↗
2021-Q3$0.1M$3.6M$14M$5.2M-$6.1M operating cash flowreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.6M$13M$1.1M$4.7M-$16M operating cash flowreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$0.6M$17M$1.5M$5.1M-$17M operating cash flowreport ↗
2022-FY$0.3M$14M$6.4M$5.0M-$19M operating cash flowreport ↗
2021-FY$0.9M$17M$8.6M$5.6M-$25M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2024-11-14Zauderer Maurice; Vaccinex (Rochester), L.L.C. · director, President and CEO, 10% owner; 10% ownerAward / grant46,153$3.25$150KForm 4
2024-11-14FRIEDBERG ALBERT; FCMI Parent Co. · director, 10% owner; 10% ownerAward / grant30,756$3.25$100KForm 4
2024-11-14FRIEDBERG ALBERT; FCMI Parent Co. · director, 10% owner; 10% ownerAward / grant (derivative)584,646$3.25$1.9MForm 4
2024-09-18FRIEDBERG ALBERT; FCMI Parent Co. · director, 10% owner; 10% ownerOption exercise214,286$5.64$1.2MForm 4
2024-09-18Zauderer Maurice; Vaccinex (Rochester), L.L.C. · director, President and CEO, 10% owner; 10% ownerOption exercise38,610$5.64$218KForm 4
2024-09-18FRIEDBERG ALBERT; FCMI Parent Co. · director, 10% owner; 10% ownerOption exercise25,723$5.64$145KForm 4
2024-09-18Zauderer Maurice; Vaccinex (Rochester), L.L.C. · director, President and CEO, 10% owner; 10% ownerOption exercise29,557$5.64$167KForm 4
2024-09-18FRIEDBERG ALBERT; FCMI Parent Co. · director, 10% owner; 10% ownerOption exercise (derivative)214,286——Form 4